<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04412811</url>
  </required_header>
  <id_info>
    <org_study_id>CYTOALLO GITMO-AMCLI SURVEY</org_study_id>
    <nct_id>NCT04412811</nct_id>
  </id_info>
  <brief_title>Prospective Survey of CMV, Herpesviruses Infections and Diseases in Allo-HSCT</brief_title>
  <acronym>CYTOALLOSURVEY</acronym>
  <official_title>A Prospective, Multicenter Survey of Cytomegalovirus (CMV) and Other Herpesviruses Infections and Diseases in Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT) Recipients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Trapianto di Midollo Osseo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Azienda Policlinico Umberto I</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gruppo Italiano Trapianto di Midollo Osseo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective observational study of epidemiological surveillance, multicenter, non-profit,&#xD;
      spontaneous, Italian with objective to describe the incidence of CMV infections and diseases&#xD;
      in adult and pediatric patients undergoing allo-HSCT during the first 6 months from&#xD;
      transplant. This study will evaluate approximately 1500 subjects (with competitive enrolment)&#xD;
      from GITMO investigational centers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective observational study of epidemiological surveillance, multicenter,&#xD;
      non-profit, spontaneous, italian on patients submitted to allogeneic haematopoietic stem cell&#xD;
      transplantation organized under the auspices of the Gruppo Italiano Trapianti di Midollo&#xD;
      Osseo that involves the principal Centres active in transplantation of any kind of&#xD;
      hematopoietic stem cells in Italy.&#xD;
&#xD;
      Allogeneic haematopoietic stem cell transplantation patients continue to be one of the&#xD;
      highest risk categories for developing viral infections. Cytomegalovirus infection is the&#xD;
      leading viral cause of morbidity and mortality and HHV6 and EBV are other major causes of&#xD;
      complications in transplant. The risk of these infections is directly related to the type of&#xD;
      transplant.&#xD;
&#xD;
      A better and continuous monitoring of Cytomegalovirus and other herpesviruses complication in&#xD;
      this setting would contribute to a better knowledge of the evolving epidemiology and would&#xD;
      lead to a better use of diagnostic strategies and of preventive and therapeutic measures.&#xD;
&#xD;
      This study is aimed to identify epidemiological characteristics of allogeneic haematopoietic&#xD;
      stem cell transplantation patients developing cytomegalovirus and other herpesviruses&#xD;
      infections, risk factors, diagnostic peculiarities and factors that may guide to pre-emptive&#xD;
      therapy versus prophylaxis strategies.&#xD;
&#xD;
      Virological monitoring and health care resources utilization in Allogeneic haematopoietic&#xD;
      stem cell transplantation recipients according to the different risk of viral infection will&#xD;
      be also assessed. This prospective analysis will provide useful information for local&#xD;
      clinicians to define tailored antiviral strategies in line with the change of transplantation&#xD;
      procedures.&#xD;
&#xD;
      All consecutive patients submitted to allogeneic haematopoietic stem cell transplantation&#xD;
      will be prospectively monitored for Cytomegalovirus Cytomegalovirus, Herpesvirus human 6 and&#xD;
      Virus Epstein-Barr infections and diseases during the six months from transplant, because&#xD;
      most of viral infections and diseases occur within this period after transplant. Risk&#xD;
      factors, incidence and prognostic factors of each viral infection and disease, as well as&#xD;
      diagnostic and therapeutic strategies employed in the various transplant centers, will be&#xD;
      evaluated in the overall population and in subpopulations according to different transplant&#xD;
      characteristics.&#xD;
&#xD;
      The incidence of these infections and diseases will be also collected and described according&#xD;
      to the different types of transplant and underlying disease conditions.&#xD;
&#xD;
      The Secondary Objectives are:&#xD;
&#xD;
      To assess the factors that may affect the incidence and the prognosis of allogeneic&#xD;
      haematopoietic stem cell transplantation infections and diseases, as well as of Herpesvirus&#xD;
      human 6 and Virus Epstein-Barr infections and related diseases To assess the impact of&#xD;
      allogeneic haematopoietic stem cell transplantation infections and diseases on the overall&#xD;
      and attributable mortality at 12 months from the transplant To describe the virological&#xD;
      diagnostic strategies of allogeneic haematopoietic stem cell transplantation, Herpesvirus&#xD;
      human 6 and Virus Epstein-Barr infections and the allogeneic haematopoietic stem cell&#xD;
      transplantation specific immunological reconstitution tests used in the various centres To&#xD;
      describe the antiviral strategies employed in the various centers and in the various&#xD;
      subpopulations of transplant patients with focus on use of antiviral drugs in prophylaxis and&#xD;
      therapy and use of allogeneic haematopoietic stem cell transplantation -specific intravenous&#xD;
      IVIG in prophylaxis and therapy To evaluate the impact of a local strategy about use of&#xD;
      antiviral drugs and allogeneic haematopoietic stem cell transplantation -specific IVIG in&#xD;
      prophylaxis and therapy on the epidemiological findings, the clinical evolution of the&#xD;
      allogeneic haematopoietic stem cell transplantation infections and diseases and on the Health&#xD;
      Care Resources utilization (diagnostic procedures, pharmaco-utilization, hospitalization,&#xD;
      outpatient visits).&#xD;
&#xD;
      A web system data entry will be used for this study. Data will be stored using specific&#xD;
      e-CRFs designed by GITMO committee and includes mainly descriptive variables. Data Center&#xD;
      will perform extensive consistency checks and issue electronic Query Forms in case of&#xD;
      inconsistent data. Follow-up period for the evaluation of survival will be from the date of&#xD;
      transplant until 12 months post-transplant or death. However, patients may not have 12 months&#xD;
      follow up and if the patients are not having 12 months of observation due to lost to follow&#xD;
      up and not due to mortality, these patients characteristics will be compared with the rest of&#xD;
      the patients in order to ascertain there is no bias or estimate the bias.&#xD;
&#xD;
      The study will be conducted according to the principles of Good Clinical Practice, the&#xD;
      current Italian and European laws and regulations, in agreement with the declaration of&#xD;
      Helsinki. The protocol has been written and the study will be conducted according to The&#xD;
      International Council for Harmonisation of Technical Requirements for Pharmaceuticals for&#xD;
      Human Use Harmonized Tripartite Guideline for Good Clinical Practice, issued by the European&#xD;
      Union. The responsible Local Ethical Committee approval must be obtained before starting the&#xD;
      trial. A copy of the patient informed consent form must be submitted to the appropriate&#xD;
      authority or committee, together with the protocol for written approval. Written approval of&#xD;
      the protocol and informed consent by the responsible and appropriate authority or committee&#xD;
      must be obtained prior to recruitment of patients to the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cytomegalovirus infection</measure>
    <time_frame>6 months from transplant</time_frame>
    <description>incidence of Cytomegalovirus after allogeneic haematopoietic stem cell transplantation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytomegalovirus disease</measure>
    <time_frame>6 months from transplant</time_frame>
    <description>incidence of Cytomegalovirus after allogeneic haematopoietic stem cell transplantation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Herpesvirus human 6 infection</measure>
    <time_frame>6 months from transplant</time_frame>
    <description>incidence of human 6 infection after allogeneic haematopoietic stem cell transplantation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Herpesvirus human 6 disease</measure>
    <time_frame>6 months from transplant</time_frame>
    <description>incidence of human 6 disease after allogeneic haematopoietic stem cell transplantation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Virus Epstein-Barr infection</measure>
    <time_frame>6 months from transplant</time_frame>
    <description>incidence of Virus Epstein-Barr infections after allogeneic haematopoietic stem cell transplantation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Virus Epstein-Barr disease</measure>
    <time_frame>6 months from transplant</time_frame>
    <description>incidence of Virus Epstein-Barr disease after allogeneic haematopoietic stem cell transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>These outcome measures will be assessed at 1 year from transplant</time_frame>
    <description>OS is defined as the time from transplant to the date of death due to any cause or to the last date the patient was known to be alive (censored observation) or to the date of the data cut-off for final analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival (DFS)</measure>
    <time_frame>These outcome measures will be assessed at 1 year from transplant</time_frame>
    <description>DFS is defined as the probability of being alive free of disease at any point in time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant Related Mortality (TRM)</measure>
    <time_frame>These outcome measures will be assessed at 1 year from transplant</time_frame>
    <description>TRM was defined as death due to any transplantation-related cause other than disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse risk (RR)</measure>
    <time_frame>These outcome measures will be assessed at 1 year from transplant</time_frame>
    <description>RR or risk ratio is the ratio of the probability of an outcome in an exposed group to the probability of an outcome in an unexposed group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Graft-versus-Host Disease</measure>
    <time_frame>These outcome measures will be assessed at 100 days from transplant</time_frame>
    <description>cumulative incidence of acute GvHD (grade II-IV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chronic graft-versus-host disease</measure>
    <time_frame>These outcome measures will be assessed at 1 year from transplant</time_frame>
    <description>cumulative incidence and severity of chronic graft-versus-host disease</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Hematologic Diseases</condition>
  <condition>Stem Cell Transplant Complications</condition>
  <condition>Cytomegalovirus Viremia</condition>
  <condition>Herpesvirus Infection</condition>
  <arm_group>
    <arm_group_label>Patients with hematological disease</arm_group_label>
    <description>Adult and children allogenic Hematopoietic stem cell transplantation recipients</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult and children allogenic Hematopoietic stem cell transplantation recipients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Prospective observational study of epidemiological surveillance, multicenter,&#xD;
             non-profit, spontaneous, Italian with objective to describe the incidence of CMV&#xD;
             infections and diseases in adult and pediatric patients undergoing allo-HSCT during&#xD;
             the first 6 months from transplant. This study will evaluate approximately 1500&#xD;
             subjects, with competitive enrolment from GITMO investigational centers.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Absence of consent Written information&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corrado Girmenia</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Policlinico Umberto I</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Angela Gheorghiu</last_name>
    <phone>0039 02 2643 6293</phone>
    <email>trialoffice@gitmo.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Massimo Martino</last_name>
    <email>Segreteria.presidenza@gitmo.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UO Ematologia e TMO - Ospedale C. Panico</name>
      <address>
        <city>Tricase</city>
        <state>Lecce</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincenzo Pavone, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vincenzo Pavone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Ospedali Riuniti</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Attilio Olivieri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Mazzoni</name>
      <address>
        <city>Ascoli Piceno</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Piero Galieni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.S. G. Moscati</name>
      <address>
        <city>Avellino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Policlinico di Bari-Ematologia con trapianti</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia - Ospedali Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Caterina Micò, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. Policlinico S.Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Arcangelo Prete</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Orsola</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Francesca Bonifazi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale Generale- Divisione Ematologia</name>
      <address>
        <city>Bolzano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Davide Nappi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AO Spedali Civili di Brescia- USD - TMO Adulti</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michele Malagola, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Locale Br1 Ospedale &quot;A. Perrino</name>
      <address>
        <city>Brindisi</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Domenico Pastore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CTMO PO &quot;Businco&quot; A.O. &quot;G. Brotzu&quot;</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Ferrarotto</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Salvatore Leotta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Struttura Complessa di Ematologia, Azienda Ospedaliera Santa Croce e Carle</name>
      <address>
        <city>Cuneo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roberto Sorasio, MD</last_name>
    </contact>
    <investigator>
      <last_name>Roberto Sorasio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Careggi</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ilaria Cutini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ematologia e Centro Trapianti Midollo Osseo - Ospedale IRCCS Casa Sollievo della Sofferenza</name>
      <address>
        <city>Foggia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Angelo Michele Carella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU-IRCCS San Martino-IST</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alida Dominietto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Gaslini</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maura Faraci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico VIto Fazzi</name>
      <address>
        <city>Lecce</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Nicola Di Renzo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Integrata</name>
      <address>
        <city>Mestre</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia - Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Consuelo Corti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione Ematologia - Azienda Ospedaliera Universitaria - Policlinico -</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mario Luppi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Elisabetta Terruzzi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. Policlinico Federico II</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Fabrizio Pane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU S. Giovanni di Dio e Ruggi D'Aragona</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uoc Sit Tmo</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Francesco Paolo Tambaro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOSC Ematologia con Trapianto CSE, AORN A. Cardarelli, AORN Cardarelli</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra Picardi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alessandra Picardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Elisabetta Calore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CTMO Osp. V. Cervello Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Indovina, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alessandro Indovina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda ospedaliera Universitaria di Parma</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Lucia Prezioso</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Maria della Misericordia</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alessandra Carotti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dip. di Ematologia - Unità di Terapia Intensiva Ematologica per il Trapianto Emopoietico - Ospedale Civile di Pescara</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Stella Santarone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mario Petrini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Carlo</name>
      <address>
        <city>Potenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Unico Regionale Trapianti di Midollo Osseo - Ospedale Bianchi-Melacino-Morelli</name>
      <address>
        <city>Reggio Calabria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Massimo Martino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arciospedale S. M. Novella</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Luca Facchini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia - Istituto di Semeiotica Medica - Policlinico A. Gemelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Patrizia Chiusolo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Bambin Gesù</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Federica Galaverna</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Tor Vergata</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raffaella Cerretti, MD</last_name>
    </contact>
    <investigator>
      <last_name>Raffaella Cerretti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Corrado Girmenia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Oncologia Medica ed Ematologia - Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano (MI)</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stefania Bramanti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Moscati</name>
      <address>
        <city>Taranto</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Patrizio Mazza</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU CIttà della Salute e della Scienza</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alessandro Busca</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Regina Margherita</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O. Santa Maria della Misericordia</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Francesca Patriarca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico GB Rossi</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Simone Cesaro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 29, 2020</study_first_submitted>
  <study_first_submitted_qc>May 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2020</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Haematopoietic transplantation, CMV, Herpesviruses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Viremia</mesh_term>
    <mesh_term>Herpesviridae Infections</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

